STNM1 in human cancers: role, function and potential therapy sensitizer
STNM1 in human cancers: role, function and potential therapy sensitizer
复制标题
DOI：
10.1016/j.cellsig.2023.110775
复制
发表时间：
2023-06-21
影响因子：
4.8
通讯作者：
Zhang，Haibo
中科院分区：
文献类型：
--
作者：
Liu，Ruiqi;Liang，Xiaodong;Zhang，Haibo
STMN1属于statthmin基因家族，它编码一种细胞质磷酸化蛋白statthmin1，这种蛋白在脊椎动物细胞中很常见。STMN1是一种结构微管相关蛋白（MAP），它结合微管蛋白二聚体而不是微管，每个STMN1结合两个微管蛋白二聚体并阻止它们聚集，导致微管不稳定。STMN1在许多恶性肿瘤中表达升高，抑制其表达可干扰肿瘤细胞分裂。它的表达可以改变肿瘤细胞的分裂，从而在G2/M期阻止细胞生长。此外，STMN1表达影响肿瘤细胞对抗微管药物类似物的敏感性，包括长春新碱和紫杉醇。目前对MAPs的研究有限，对STMN1在不同癌症中的作用机制有了新的认识。STMN1在癌症预后和治疗中的有效应用需要进一步了解该蛋白。在这里，我们总结了STMN1的一般特征，并概述了STMN1如何在癌症发展中发挥作用，靶向多个信号网络，并作为多种microrna， circrna和lincrna的下游靶标。我们还总结了STMN1在肿瘤耐药中的功能作用和作为癌症治疗靶点的最新发现。
STMN1 belongs to the stathmin gene family, it encodes a cytoplasmic phosphorylated protein, stathmin1, which is commonly observed in vertebrate cells. STMN1 is a structural microtubule-associated protein (MAP) that binds to microtubule protein dimers rather than microtubules, with each STMN1 binding two microtubule protein dimers and preventing their aggregation, leading to microtubule instability. STMN1 expression is elevated in a number of malignancies, and inhibition of its expression can interfere with tumor cell division. Its expression can change the division of tumor cells, thereby arresting cell growth in the G2/M phase. Moreover, STMN1 expression affects tumor cell sensitivity to anti-microtubule drug analogs, including vincristine and paclitaxel. The research on MAPs is limited, and new insights on the mechanism of STMN1 in different cancers are emerging. The effective application of STMN1 in cancer prognosis and treatment requires further understanding of this protein. Here, we summarize the general characteristics of STMN1 and outline how STMN1 plays a role in cancer development, targeting multiple signaling networks and acting as a downstream target for multiple microRNAs, circRNAs, and lincRNAs. We also summarize recent findings on the function role of STMN1 in tumor resistance and as a therapeutic target for cancer.